Influence of the severity of cognitive impairment on the effect of the Ginkgo biloba extract EGb 761® in Alzheimer's disease

Neuropsychobiology

Volumn 45, Issue 1, 2002, Pages 19-26

  Le Bars, P L ^a   Velasco, F M ^b   Ferguson, J M ^c   Dessain, E C ^d   Kieser, Meinhard ^e   Hoerr, R ^e  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b HZI Research Center   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

Author keywords

Alzheimer's disease; Dementia; EGb 761 ; Geriatric Evaluation by Relatives Rating Instrument; Ginkgo; Mini Mental State Examination

Indexed keywords

GINKGO BILOBA EXTRACT; PLACEBO;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SOCIAL INTERACTION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BOSTON; COGNITION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GERMANY; GINKGO BILOBA; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; NEW YORK CITY; PHYTOTHERAPY; PLANT EXTRACTS; SEVERITY OF ILLNESS INDEX; SOCIAL BEHAVIOR; TREATMENT OUTCOME; UTAH;

EID: 0036164525     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048668     Document Type: Article

References (53)

1. Ginkgo biloba for cerebral insufficiency
2. Nootropics: Efficacy and tolerability of products from three active substance classes
3. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease
4. Ginkgo biloba extract in the treatment of primary degenerative dementia. Placebo-controlled double-blind and comparative study
5. The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation
6. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia
7. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type
8. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia
9. Longitudinal evaluation of dementia of the Alzheimer type: A comparison of 3 standardized mental status examinations
10. Progression of cognitive impairment in Alzheimer's disease
11. The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease
12. Comparison of rate of annual change of mental status score in four independent studies of patients with Alzheimer's disease
13. Mild senile dementia of the Alzheimer type. Evaluation of intervention
14. A longitudinal study of Alzheimer's disease: Measurement, rate, and predictors of cognitive deterioration
15. Cognitive test performance in detecting, staging, and tracking Alzheimer's disease
16. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop
17. The stages of Alzheimer's disease: A reappraisal
18. Lipid peroxide, phospholipids, glutathione levels and superoxide dismutase activity in rat brain after ischaemia: Effect of Ginkgo biloba extract
19. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by β-amyloid
20. The effects of chronic, oral Ginkgo biloba extract administration on neurotransmitter receptor binding in young and aged Fisher 344 rats
21. 1A receptors during ageing: Reversal by Ginkgo biloba extract (EGb 761)
22. Changes of high-affinity choline uptake in the hippocampus of old rats after long-term administration of two nootropic drugs (tacrine and Ginkgo biloba extract)
23. Effects of an extract of Ginkgo biloba on rat brain energy metabolism in hypoxia
24. Effets de l'extrait de Ginkgo biloba sur un modèle d'ischémie cérébrale chez la gerbille
25. Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb 761)
26. Ginkgo biloba extract (EGb 761) protects Na,K-ATPase activity during cerebral ischemia in mice
27. A new rating scale for Alzheimer's disease
28. Development and validation of the Geriatric Evaluation by Relatives Rating Instrument (GERRI)
29. Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures
30. Clinical staging of dementia in a population survey: Comparison of DSM-II-R and the Washington University Clinical Dementia Rating Scale
31. Clinical predictors of course for Alzheimer patients in a longitudinal study: A preliminary report
32. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease
33. A 24-week, double blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
34. Tutorial on modeling ordered categorical response data
35. 'Mini-Mental State'. A practical method for grading the cognitive state of patients for the clinician
36. Limits of the 'Mini-Mental State' as a screening test for dementia and delirium among hospital patients
37. Nimodipine in the treatment of probable Alzheimer's disease. Results of two multicenter trials
38. The Alzheimer's disease assessment scale: Patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials
39. The validity of informant reports in assessing the severity of dementia: Evidence from the CAMDEX interview
40. The Mini-Mental State Examination in the early diagnosis of Alzheimer's disease
41. Population-based norms for the Mini-Mental State Examination by age and educational level
42. Language comprehension profiles in Alzheimer's disease, multi-infarct dementia, and frontotemporal degeneration
43. Diagnosis of dementia. Methods for interpretation of scores of 5 neuropsychological tests
44. Early diagnosis of dementia: Neuropsychology
45. A longitudinal population study of the Mini-Mental State Examination in the very old: Relation to dementia and dducation
46. Efficacy and safety of BMY 21,502 in Alzheimer disease
47. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease
48. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: A review of phase III trials
49. Rate of progression of Alzheimer's disease
50. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
51. The effects of donepezil in Alzheimer's disease - Results from a multinational trial